PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis.

  • M Untch
  • G von Minckwitz
  • G E Konecny
  • U Conrad
  • W Fett
  • C Kurzeder
  • H-J Lück
  • E Stickeler
  • H Urbaczyk
  • B Liedtke
  • M W Beckmann
  • C Salat
  • N Harbeck
  • Volkmar Müller
  • M Schmidt
  • S Hasmüller
  • M Lenhard
  • V Nekljudova
  • Annette Lebeau
  • S Loibl
  • P A Fasching
  • Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE Investigators

Abstract

The objective of this study was to compare the effect of dose-intensified neoadjuvant chemotherapy with that of standard epirubicin plus cyclophosphamide followed by paclitaxel in combination with or without darbepoetin on survival in primary breast cancer.

Bibliografische Daten

OriginalspracheEnglisch
Aufsatznummer9
ISSN0923-7534
StatusVeröffentlicht - 2011
pubmed 21382868